Cutaneous Lymphoma
Cutaneous lymphomas are a group of non-Hodgkin lymphomas in which abnormal T or B lymphocytes multiply and accumulate in the skin, with no evidence of systemic involvement (lymph nodes, bone marrow, internal organs) at the time of diagnosis. They fall into two main groups: cutaneous T-cell lymphoma (CTCL), which accounts for about 75–80% of cases, and cutaneous B-cell lymphoma (CBCL), which accounts for about 20–25%.
The biggest clinical challenge is that early CTCL looks remarkably like common benign inflammatory skin conditions such as atopic dermatitis, psoriasis, fungal infection or seborrheic dermatitis. As a result, many patients are diagnosed years, or even decades, late.
At Haute-Derma, we follow a rigorous microscopic diagnostic pathway that combines detailed immunohistochemistry (IHC), T- and B-cell receptor gene rearrangement studies (TCR/BCR), and imaging to screen for systemic spread. Our integrated treatment strategy, ranging from skin-directed therapies to systemic treatment, aims for long-term disease control and a better quality of life.
Clinical and Pathological Features
Clinical and Pathological Classification
Cutaneous T-Cell Lymphoma (CTCL)
- Mycosis fungoides (MF):
- The most common type of CTCL (> 50%). It typically progresses through three clinical stages: patch phase, then plaque phase, then tumor phase.
- Histopathology: Atypical T lymphocytes with brain-like (cerebriform) nuclei migrate into the epidermis (epidermotropism) and gather in small characteristic clusters called Pautrier microabscesses.
- Sézary syndrome (SS): An aggressive, systemic form of CTCL defined by a triad of whole-body redness (erythroderma), generalized lymph node enlargement (lymphadenopathy) and circulating Sézary cells in the blood (≥ 1,000 cells/µL or a CD4/CD8 ratio ≥ 10).
- CD30-positive lymphoproliferative disorders: These include lymphomatoid papulosis (LyP) and anaplastic large cell lymphoma (ALCL).
Cutaneous B-Cell Lymphoma (CBCL)
Unlike CTCL, which tends to invade the epidermis, CBCL usually sits in the dermis and subcutis. It appears as smooth, red-purple nodules or masses that do not involve the epidermis (no epidermotropism).
- Primary cutaneous follicle center lymphoma (PCFCL): An excellent outlook; atypical lymphoid follicles are seen in the dermis.
- Primary cutaneous marginal zone lymphoma (PCMZL): A good outlook, partly linked to chronic infection (Borrelia burgdorferi).
- Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT): A highly aggressive CBCL, usually on the legs of older adults, that spreads quickly and needs intensive chemotherapy.
Differential Diagnosis and Immunohistochemistry (IHC)
| Condition | Immunohistochemical (IHC) Markers and Microscopic Features |
|---|---|
| Mycosis fungoides (MF) | CD3+; CD4+; CD45RO+; loss of CD7 or CD2; CD8− (in most cases); epidermotropism present; Pautrier microabscesses present. |
| CD30+ lymphoma (LyP / ALCL) | Strong CD30 positivity in > 75% of large atypical cells; CD3+; CD4+. |
| Cutaneous B-cell lymphoma (PCFCL / PCMZL) | CD20+; CD79a+; PAX5+; BCL-2 +/−; CD3−; CD4−. |
| Atopic dermatitis / psoriasis (benign) | Reactive inflammatory T cells express the full set of CD3, CD4, CD8 and CD7; no cerebriform nuclei; polyclonal (not a single clone). |
Our Approach to Cutaneous Lymphoma
At Haute-Derma, we manage cutaneous lymphoma according to a personalized-medicine standard:
- Multiple punch biopsies: Samples are taken from several different red patches or tumors to improve the accuracy of the pathology.
- Clonality testing: PCR analysis of TCR (gamma or beta) or BCR gene rearrangement confirms a malignant monoclonal expansion of T or B cells.
- Whole-body staging (ISCL/EORTC): Staging by TNMB criteria (tumor, node, metastasis, blood) defines how far the disease has spread.
- Skin-directed therapy first in early disease: We avoid overusing systemic chemotherapy, with its unnecessary toxicity, while the disease is still superficial (T1–T2).
How Cutaneous Lymphoma Is Diagnosed at Haute-Derma
So that early CTCL is not missed and the subtype is clearly defined, Haute-Derma follows a four-step pathway:
- Clinical examination and high-resolution dermoscopy: We look for mildly scaly red patches with irregular, winding shapes, spermatozoa-like or dotted vessels on dermoscopy, and an atypical orange to pale pink color.
- Deep punch or incisional biopsy: The sample includes the full epidermis, dermis and upper subcutis so the density of the lymphocytic infiltrate can be assessed.
- Immunohistochemistry and molecular testing: A panel of CD3, CD4, CD8, CD7, CD20, CD30 and Ki-67 stains, combined with PCR for TCR/BCR gene rearrangement.
- Systemic assessment and imaging: Whole-body PET/CT, ultrasound of regional lymph nodes and a peripheral blood smear (looking for Sézary cells) to check for spread to lymph nodes and internal organs.
How Cutaneous Lymphoma Is Treated at Haute-Derma
Treatment depends on the type of lymphoma (T-cell vs. B-cell) and its ISCL/EORTC stage:
- Skin-directed therapies (for early-stage MF/CTCL, IA–IIA):
- Potent topical corticosteroids: First choice for localized, thin patches.
- Topical chemotherapy: Mechlorethamine (nitrogen mustard) gel or bexarotene 1% gel (a newer-generation retinoid).
- Phototherapy: Narrowband UVB (NB-UVB) for thin patches, or PUVA (psoralen plus UVA) for thicker, more infiltrated plaques.
- Total skin electron beam therapy (TSEB) or local radiotherapy: Superficial radiation that works very well for tumors or persistent widespread disease.
- Systemic therapies (for advanced CTCL, Sézary syndrome and aggressive CBCL):
- Immunomodulators and retinoids: interferon-alpha or oral bexarotene.
- Monoclonal antibodies and targeted therapy:
- Mogamulizumab (an anti-CCR4 antibody) for Sézary syndrome and widespread MF.
- Brentuximab vedotin (an anti-CD30 antibody–drug conjugate) for CD30+ lymphomas.
- Rituximab (an anti-CD20 antibody), the gold standard for cutaneous B-cell lymphoma (CBCL).
- Extracorporeal photopheresis (ECP): A leading selective immunotherapy for Sézary syndrome.
